Engineered extracellular vesicles in female reproductive disorders

Zhang, Mengxue; Xing, Jie; Zhao, Shijie; Chen, Hui; Yin, Xiaoxing; Zhu, Xiaolan

doi:10.1016/j.biopha.2023.115284

Cited by 5 publications

(1 citation statement)

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the help of nanoscience, reproductive assistive technology has revolutionized the field of fertility treatments, and scientists have been able to develop innovative methods that improve the success rates of procedures such as in vitro fertilization (IVF) and sperm selection by utilizing nanotechnology . The incorporation of several drugs into nanocarriers, such as acyclovir, emtricitabine, and remdesivir, allows for targeted delivery and improved efficacy in treating reproductive infections and disorders.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Nanotechnology-Based Drug Delivery Systems for the Diagnosis and Treatment of Reproductive Disorders

Acharya,

Behera,

Behera

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Over the past decade, nanotechnology has seen extensive integration into biomedical applications, playing a crucial role in biodetection, drug delivery, and diagnostic imaging. This is especially important in reproductive health care, which has become an emerging and significant area of research. Global concerns have intensified around disorders such as infertility, endometriosis, ectopic pregnancy, erectile dysfunction, benign prostate hyperplasia, sexually transmitted infections, and reproductive cancers. Nanotechnology presents promising solutions to address these concerns by introducing innovative tools and techniques, facilitating early detection, targeted drug delivery, and improved imaging capabilities. Through the utilization of nanoscale materials and devices, researchers can craft treatments that are not only more precise but also more effective, significantly enhancing outcomes in reproductive healthcare. Looking forward, the future of nanotechnology in reproductive medicine holds immense potential for reshaping diagnostics, personalized therapies, and fertility preservation. The utilization of nanotechnology-driven drug delivery systems is anticipated to elevate treatment effectiveness, minimize side effects, and offer patients therapies that are not only more precise but also more efficient. This review aims to delve into the various types, properties, and preparation techniques of nanocarriers specifically designed for drug delivery in the context of reproductive disorders, shedding light on the current landscape and potential future directions in this dynamic field.

show abstract

Section: Introductionmentioning

confidence: 99%

Recent Advances in Nanotechnology-Based Drug Delivery Systems for the Diagnosis and Treatment of Reproductive Disorders

Acharya,

Behera,

Behera

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

Gene Therapy for Inflammatory Cascade in Intrauterine Injury with Engineered Extracellular Vesicles Hybrid Snail Mucus‐enhanced Adhesive Hydrogels

Peng,

Wang,

Dai

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Early hyper‐inflammation caused by intrauterine injury triggered subsequent intrauterine adhesion (IUA). STAT1‐mediated M1 macrophages are confirmed to secrete pro‐inflammatory cytokines to accelerate inflammatory cascade and IUA formation by multi‐omics analysis and experimental verification. However, clinically used hyaluronic acid (HA) hydrogels are prone to slip out of injury sites due to poor bio‐adhesion properties. Therefore, there are still challenges in applying hydrogels for M1 macrophage intervention in IUA treatment. Herein, an engineered extracellular vesicles (EVs) hybrid snail mucus (SM)‐enhanced adhesive hydrogels to improve bio‐adhesion property is fabricated and M1 macrophage intervention through targeting delivery and STAT1 silencing is achieved. First, inspired by the high bio‐adhesion capacity of SM, SM and gelatin methacrylate (GelMA) solution are mixed to construct GelMA/SM (GS) hydrogel. Then, folic acid‐modified extracellular vesicles (FA‐EVs) are synthesized for targeting the delivery of STAT1‐siRNA. Upon injection of FA‐EVs hybrid GS hydrogel into the uterine cavity, a protective hydrogel layer forms on the surface of injury sites and sustains the release of STAT1‐siRNA‐loaded FA‐EVs to curtail M1 macrophages generation through inhibiting STAT1 phosphorylation, resulting in reduction of myofibroblasts activation and collagen deposition. In addition, the pregnancy rate and the number of fetuses in rats treated with this hydrogel were much higher than those in other groups, suggesting that the hydrogel could promote functional endometrial regeneration and restore fertility. Overall, this study presents a promising strategy for employing FA‐EVs hybrid adhesive hydrogel with superior bio‐adhesion properties and M1 macrophage targeting delivery for IUA treatment and uterus recovery.

show abstract